Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
Condition(s):Severe Acute Respiratory Syndrome Coronavirus 2Last Updated:April 24, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Severe Acute Respiratory Syndrome Coronavirus 2Last Updated:April 24, 2020Unknown status
Condition(s):Acute Lung InjuryLast Updated:September 10, 2019Completed
Condition(s):Acute Respiratory Distress Syndrome (ARDS)Last Updated:April 28, 2015Completed
Condition(s):Acute Respiratory Distress SyndromeLast Updated:March 13, 2024Recruiting
Condition(s):Respiratory Distress Syndrome, Adult; Acute Lung Injury; Acute Respiratory Distress SyndromeLast Updated:October 3, 2011Completed
Condition(s):Respiratory Distress Syndrome; Respiratory Distress Syndrome, AdultLast Updated:March 18, 2024Completed
Condition(s):Adult Respiratory Distress Syndrome; Acute Lung InjuryLast Updated:January 7, 2014Withdrawn
Condition(s):Acute Respiratory Distress SyndromeLast Updated:May 6, 2023Recruiting
Condition(s):Acute Respiratory Distress SyndromeLast Updated:May 20, 2020Completed
Condition(s):Respiratory Distress Syndrome, AdultLast Updated:November 8, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.